First Light Asset Management LLC Makes New $9.72 Million Investment in Spyglass Pharma, Inc. $SGP

First Light Asset Management LLC purchased a new stake in shares of Spyglass Pharma, Inc. (NASDAQ:SGP) during the first quarter, according to its most recent filing with the Securities & Exchange Commission. The firm purchased 375,000 shares of the company’s stock, valued at approximately $9,716,000. First Light Asset Management LLC owned about 1.12% of Spyglass Pharma at the end of the most recent reporting period.

Separately, Affinity Asset Advisors LLC purchased a new stake in shares of Spyglass Pharma in the 1st quarter valued at $6,478,000.

Spyglass Pharma Stock Performance

SGP stock opened at $20.49 on Monday. Spyglass Pharma, Inc. has a 52 week low of $17.06 and a 52 week high of $32.44. The firm’s fifty day simple moving average is $19.82. The company has a market cap of $685.04 million and a price-to-earnings ratio of -3.20.

Spyglass Pharma (NASDAQ:SGP) last posted its quarterly earnings results on Thursday, May 14th. The company reported ($0.69) earnings per share for the quarter, missing the consensus estimate of ($0.67) by ($0.02).

Spyglass Pharma Profile

We are a late-stage biopharmaceutical company dedicated to transforming the treatment paradigm for patients living with chronic eye conditions through long-acting, sustained drug delivery of approved medicines. Our mission is to significantly improve the lives of patients with chronic eye conditions by developing durable drug delivery solutions that can empower patients and surgeons with confidence in long-term disease control and vision preservation. Our lead product candidate, the Bimatoprost Drug Pad-IOL System (BIM-IOL System), comprising novel, proprietary drug pads attached to our intraocular lens (IOL), is designed to be implanted during routine cataract surgery to reduce elevated intraocular pressure (IOP) in patients who have either open-angle glaucoma (OAG) or ocular hypertension (OHT).